Olanib 150 MG (Olaparib) – 120 Tablets

Description

Composition: Olanib 150 Tablet: Each flim coated tablet contains Olaparib 150 mg. 

Product Features:

What does Olanib used for?

Olanib 150 mg (Olaparib) is a targeted cancer therapy drug that belongs to a class of medications known as PARP (poly ADP-ribose polymerase) inhibitors. It is primarily used in the treatment of certain types of cancers that have specific genetic mutations, such as BRCA1 and BRCA2 mutations. These mutations are often found in breast, ovarian, pancreatic, and prostate cancers.

Breast Cancer: For patients with HER2-negative metastatic breast cancer with a germline BRCA mutation.

Ovarian Cancer: As maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Pancreatic Cancer: For patients with metastatic pancreatic cancer with a germline BRCA mutation who have been previously treated with platinum-based chemotherapy.

Prostate Cancer: For patients with metastatic castration-resistant prostate cancer with germline or somatic HRR (homologous recombination repair) gene mutations, including BRCA1 and BRCA2.

Dosage and Administration

The recommended dose of Olanib is 300 mg (two 150mg tablets) twice a day, making a total daily dose of 600 mg. Treatment should continue until the disease progresses or there are unacceptable side effects.

For patients with platinum-sensitive relapsed (PSR) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy, it is therefore strongly advised to start Olanib (olaparib) treatment within 8 weeks after the last dose of their platinum-containing regimen. Moreover, initiating treatment within this timeframe is crucial to maximize the effectiveness of the therapy. Additionally, by beginning Olanib promptly, the likelihood of maintaining the patient’s positive response to chemotherapy is significantly enhanced.

How to take Olanib?

Olanib 150 is for oral use.  Olanib 150 tablets should be swallowed whole and not chewed, crushed, dissolved or divided. You can take it with or without food.

Missed a Dose?

If you missed a dose of Olanib, take the next dose in time and skip that dose. 

Olanib 150 MG Side Effects 

Common side effects of olaparib include:

• Nausea
• Fatigue
• Vomiting
• Anemia
• Diarrhea
• Decreased appetite
• Headache
• Dysgeusia (altered taste)
• Thrombocytopenia (low platelet count)
• Neutropenia (low levels of neutrophils, a type of white blood cell)

Use in Specific Populations

Pregnancy Category D

Olaparib can harm a fetus if administered to a pregnant woman. Studies in animals show it can cause birth defects and fetal toxicity at doses lower than the recommended human dose (300 mg twice daily).

Warning: If a woman is pregnant or becomes pregnant while taking Olaparib, she should be informed about the potential risks to the fetus and the possibility of pregnancy loss.

Nursing Mothers

It is unknown if Olaparib is present in human milk.

Precaution: Due to the potential for serious side effects in nursing infants. A decision must be made to either stop breastfeeding or discontinue Olaparib, considering the drug’s importance to the mother.

Populations with Reproductive Potential

Pregnancy Testing: Recommended for women of reproductive age before starting Olanib.

Contraception: Advise women of reproductive potential to use highly effective birth control during treatment and for at least 6 months after the last dose, as Olanib can harm a fetus.

Our Shipping Countries List:

United States, Canada, Mexico, Brazil, Argentina, United Kingdom, France, Germany, Italy, Spain, Portugal, Netherlands, Belgium, Switzerland, Austria, Sweden, Norway, Denmark, Finland, Iceland, Russia, China, Japan, South Korea, North Korea, Vietnam, Thailand, Malaysia, Singapore, Indonesia, Philippines, Australia, New Zealand, South Africa, Egypt, Nigeria, Kenya, Ethiopia, Morocco, Turkey, Saudi Arabia, United Arab Emirates, Iran, Iraq, Syria, Lebanon, Jordan, Qatar, Bahrain, Kuwait, Oman, Yemen, Afghanistan, Sri Lanka, Nepal, Bhutan, Maldives, Myanmar, Cambodia, Laos, Mongolia, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Azerbaijan, Armenia, Georgia, Ukraine, Belarus, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, Greece, Albania, Serbia, Montenegro, Bosnia and Herzegovina, Croatia, Slovenia, North Macedonia, Kosovo, Malta, Cyprus, Tunisia, Algeria, Libya, Sudan, Sierra Leone, Liberia, Ivory Coast, Ghana, Uganda, Zambia, Malawi, Zimbabwe, Namibia, Angola, Somalia, Eritrea.

For other Breast cancer related product